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AbstrACt 
Introduction  Intracranial pressure (ICP) monitoring is 
commonly used in neurocritical care patients with acute 
brain injury (ABI). Practice about indications and use of 
ICP monitoring in patients with ABI remains, however, 
highly variable in high-income countries, while data on 
ICP monitoring in low and middle-income countries are 
scarce or inconsistent. The aim of the SYNAPSE-ICU study 
is to describe current practices of ICP monitoring using a 
worldwide sample and to quantify practice variations in 
ICP monitoring and management in neurocritical care ABI 
patients.
Methods and analysis The SYNAPSE-ICU study is a large 
international, prospective, observational cohort study. 
From March 2018 to March 2019, all patients fulfilling 
the following inclusion criteria will be recruited: age >18 
years; diagnosis of ABI due to primary haemorrhagic 
stroke (subarachnoid haemorrhage or intracranial 
haemorrhage) or traumatic brain injury; Glasgow Coma 
Score (GCS) with no eye opening (Eyes response=1) 
and Motor score ≤5 (not following commands) at ICU 
admission, or neuro-worsening within the first 48 hours 
with no eye opening and a Motor score decreased to 
≤5. Data related to clinical examination (GCS, pupil size 
and reactivity, Richmond Agitation-Sedation Scale score, 
neuroimaging) and to ICP interventions (Therapy Intensity 
Levels) will be recorded on admission, and at day 1, 3 and 
7. The Glasgow Outcome Scale Extended (GOSE) will be 
collected at discharge from ICU and from hospital and at 
6-month follow-up. The impact of ICP monitoring and ICP-
driven therapy on GOSE will be analysed at both patient 
and ICU level.
Ethics and dissemination The study has been approved 
by the Ethics Committee ‘Brianza’ at the Azienda Socio 
Sanitaria Territoriale (ASST)-Monza (approval date: 21 
November 2017). Each National Coordinator will notify the 
relevant ethics committee, in compliance with the local 
legislation and rules. Data will be made available to the 
scientific community by means of abstracts submitted to 
the European Society of Intensive Care Medicine annual 
conference and by scientific reports and original articles 
submitted to peer-reviewed journals.
trial registration number NCT03257904.
IntroduCtIon  
background and rationale
Intracranial pressure (ICP) monitoring is 
commonly used in neurocritical care. The 
indications for ICP monitoring, both as a 
stand-alone monitor or in association with 
other modalities (eg, brain tissue oxygen-
ation, electroencephalography, etc) are 
based on local or national policies and inter-
national guidelines.
In 2014, a multidisciplinary consensus 
statement was released to provide guidance 
on multimodality monitoring in neurocrit-
ical care, including ICP.1 In the most recent 
Brain Trauma Foundation (BTF) guide-
lines, the strength of recommendation for 
strengths and limitations of this study
 ► Data from this large cohort of acute brain injury pa-
tients admitted to the intensive care unit will provide 
a detailed description of the  patients’ characteris-
tics, intracranial pressure (ICP) management strat-
egies, resource use and their correlation to clinical 
outcomes.
 ► The results will complement other multicentre stud-
ies focusing on traumatic brain injury practice and 
will add information on ICP practice in subarachnoid 
haemorrhage and intracerebral haemorrhage.
 ► The global approach can be considered as the main 
strength and novelty of the study, since it allows to 
explore the clinical practice in geographical regions 
characterised by very different public health issues.
 ► The presence of centres in low- and middle-income 
countries will provide robust data about ICP monitor-
ing in these regions.
 ► The observational nature of the study and the con-
sequent difficulty to draw causal inferences reliably 
accounts as the main limitation of the research. The 
aim of the study is hypothesis-generating for treat-
ment effects to be assessed in large randomised 
clinical trials.
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ICP monitoring in traumatic brain injury (TBI) was 
downgraded compared with the previous editions2 and 
clinicians might feel uncertain whether and for which 
indications they should consider it.3 Furthermore, the 
BTF guidelines propose a ‘new’ threshold of 22 mm Hg 
to consider the initiation of therapies to reduce ICP. 
The strength of evidence on which the new and higher 
threshold is based is questionable, since it stems from one 
single centre retrospective observational study.4 In this 
study, the association between mean ICP and outcome 
was examined, with a nadir threshold of 22 mm Hg. 
However, the mean ICP is entirely different from a 
treatment threshold. More fundamentally, the rationale 
supporting a single number as a threshold for goal-di-
rected therapy is questionable given the complexity and 
dynamic aspects of raised ICP leading to secondary brain 
injury.5–8 The ‘dose of ICP’ concept, which was proposed 
earlier as the proportion of hourly measurements above 
20 mm Hg,9 or the area under the curve of hourly values 
above 20 mm Hg6, is a more accurate marker associated 
with outcome. Furthermore, Güiza et al showed that even 
ICP insults at lower levels between 15 and 20 mm Hg, if 
sustained, could lead to worse outcome.5 Above 20 mm 
Hg, the vast majority of insults are clearly deleterious 
when lasting more than 37 min in adults. Above 25 mm 
Hg, the association with worse Glasgow Outcome Score 
Extended (GOSE) occurs within 12 min.5 Furthermore, 
thresholds depend on age (lower thresholds in children) 
and cerebrovascular autoregulation (higher when auto-
regulation is preserved). Finally, whether threshold-based 
treatment strategies have a positive impact on outcome 
has not yet been established.10–13
In non-TBI (acute subarachnoid haemorrhage 
[SAH] and intracerebral haemorrhage [ICH]),14–17 no 
defined consensus is available to guide clinicians, since 
the indications for ICP monitoring are mostly based 
on TBI.14 The indications for ICP and cerebral perfu-
sion pressure monitoring in non-TBI patients include 
reduced Glasgow Coma Score (GCS ≤8), cerebral 
oedema on imaging, neurological worsening and mass 
effect. Intracranial hypertension (generally defined 
with ICP >20 mm Hg) is common after SAH, especially 
during the early phase of poor grade SAH. In a large 
cohort study of SAH patients, increased ICP has been 
independently associated with poor outcome when it 
lasts more than 5 min.18–21 The association with poor 
outcome has been demonstrated also in good grade 
SAH.14 There is little consensus about the duration of 
ICP monitoring after SAH or ICH, as well as specific ICP 
thresholds for treatment, and collaboratively agreed 
treatment protocols are currently lacking.
Recently, national (Australia/New Zealand) and inter-
national (Europe - CENTER-TBI) studies have explored 
practices of ICP in TBI patients and found these to be 
highly variable.22 Conversely, information on ICP moni-
toring in low- and middle-income countries is scarce and 
inconsistent in the TBI setting, and the technology for 
ICP monitoring is often lacking.23 The incidence of TBI 
is likely to be high in these countries and epidemiological 
studies are urgently needed.
A multicentre international study on ICP including 
conditions other than TBI, such as SAH and ICH, and 
including countries from different economic areas, is also 
currently missing.
Aim and objectives
The aim of the SYNAPSE-ICU study is to describe the 
current practice of ICP monitoring in neurocritical 
care and to quantify practice variations in interventions 
(measured as Therapy Intensity Level) and investiga-
tions (additional neuromonitoring and neuroimaging) 
in neurocritical care patients with TBI, SAH and ICH in 
high-, middle- and low-income countries. In addition, we 
will assess patterns of long-term functional outcome asso-
ciated with ICP monitoring and ICP-driven therapies.
MEthods And AnAlysIs
study design
We have designed a large international, prospective, 
observational cohort study aiming to recruit >2000 
patients in coma after acute traumatic and non-traumatic 
brain injury, with 6 month follow-up.
Patient and public involvement
Patients and public have not been involved in the study 
design or in the recruitment to and conduct of the study.
setting
Worldwide, 59 countries have been contacted to partic-
ipate in the SYNAPSE-ICU study (more information at 
https://www. esicm. org/ research/ trials/ trials- group- 2/ 
SYNAPSE- ICU/). We aim to obtain also the participation 
of low- and middle-income countries, usually under-rep-
resented in these studies, to improve the generalisability 
of results. The established recruitment window will open 
on the 15 March 2018 and will close on the 31 March 
2019. After 6 months from recruitment, the patients or 
their family members will be contacted by phone for the 
follow-up evaluation.
Participants
All the patients fulfilling the following inclusion criteria 
will be recruited:
1. Age >18 years,
2. Diagnosis of an acute brain injury (ABI) due to pri-
mary haemorrhagic stroke (including ICH or SAH) or 
TBI,
3. GCS with Eyes response = 1 (no eyes opening) and 
Motor score ≤5 (not following commands) at the ad-
mission to intensive care unit (ICU) or neuro-worsen-
ing within the first 48 hours with no eye opening and 
the Motor score decreased to ≤5.
Exclusion criteria:
1. ABI who are not admitted to ICU,
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2. ABI due to infections of the central nervous system, 
ischaemic stroke or other causes not defined in the in-
clusion criteria.
Provided local ethics protocols are satisfied and, if 
required, informed consent will be obtained from personal 
(next-of-kin) or professional (medical) consultees.
Variables and source of data
Demographic characteristics and past medical history 
information, including gender, age, co-morbidities (as 
well as medications and alcohol abuse) diagnosis, timing 
of acute events and clinical presentation of ABI, will be 
extracted from the patients’ medical records.
Clinical data (GCS, pupil size and reactivity, Richmond 
Agitation-Sedation Scale score, neuroimaging) and inter-
ventions (Therapy Intensity Levels) will be recorded on 
admission, and at day 1, 3 and 7. All clinical evaluations 
will be performed as per standard clinical practice.
Centres will collect the Glasgow Outcome Scale 
Extended (GOSE) at ICU and at hospital discharge. 
GOSE will also be collected at the follow-up time point, 6 
months after recruitment. The GOSE at follow-up will be 
collected via phone-structured interviews to the patients 
and/or family members using a validated question-
naire.24 Data on the cause of death will be collected as 
well.
data collection and management
Anonymised data will be collected in a web-based elec-
tronic Case-Report Form (eCRF) and protected by 
encryption software and password provided to single 
users. Each patient will be associated to a numeric code 
generated by the central database.
The eCRF has been designed to identify two paths 
according to the initial decision on ICP monitoring: in 
presence of ICP monitoring, technical (timeline, type of 
device, additional neuro-monitoring and neuroimaging 
characteristics) and clinical information about insertion 
will be documented in the eCRF-A, whereas reasons for 
not initiating ICP monitoring, additional neuro-mon-
itoring and neuroimaging data will be recorded in the 
eCRF-B. The Daily eCRF Data Capture will be completed 
for each pathway (ICP vs no-ICP) at day 1, 3 and 7 of ICU 
stay for each patient.
All data will be checked for consistency and complete-
ness by the study coordinator (EF) while data accrue, to 
ensure the high quality of the collected data before the 
analysis and to limit the rate of errors and missing data. 
Written warnings will be sent to the investigators to fix 
potential inconsistencies.
The data will be securely stored at the University Mila-
no-Bicocca; all procedures will comply with the European 
Union Regulation 2016/679 on the protection of natural 
persons regarding personal data processing and move-
ment. A Data Transfer Agreement (DTA) to confirm the 
terms for data transfer from the SYNAPSE-ICU centres to 
the Sponsor has been finalised.
study size
The primary endpoint is the variation in clinical practice 
around ICP monitoring in acute brain injury patients. 
The hypotheses of the study are exploratory; hence, a 
sample size calculation has not been conducted.
This study aims to recruit >2000 patients in coma 
after acute traumatic and non-traumatic brain damage 
admitted to more than 200 ICUs. These sample sizes of 
the patients and ICUs will allow capturing the variation 
in ICP related practice among ICUs. The recruitment 
will last 12 weeks at each centre, or the duration required 
to enrol 90 patients per centre; the study, therefore, will 
likely be completed around September 2019, once the 
last recruited patient (ie, 31 March 2019) undergoes the 
follow-up assessment (ie, 30 September 2019).
Sampling and selection bias due to over-representation 
of some centres may skew the results. To avoid this type of 
bias, we limited the data collection to 30 patients/centre 
per diagnosis at presentation (30 patients with TBI, 30 
with SAH and 30 with ICH).
statistical methods
Descriptive statistics will be used to summarise the 
patients’ characteristics. Practice variation in interven-
tions and investigations will be quantified using random 
effect models with a random intercept for ICU and/
or geographic region, dependent on the distribution 
of participating ICUs over different countries. We will 
explore the impact of the patient and ICU characteris-
tics on treatment decisions. For the patient characteris-
tics and interventions that are measured repeatedly in a 
single patient, a random intercept for the patient will be 
added to consider the within-patient correlation. Practice 
variation will be quantified with the median OR, which 
translates the ICU level variance in the widely used OR 
scale.25 26
To assess patterns of long-term functional outcome 
associated with ICP monitoring and ICP-driven therapy, 
two approaches will be taken: one at the patient level and 
one at the ICU level.
For the patient level analysis, a proportional odds 
regression model will be constructed with the GOSE at 
6 months as dependent variable and the treatment of 
interest as independent variable, adjusted for relevant 
patient characteristics. A propensity score approach will 
be used to estimate the likelihood of treatment based on 
the patient characteristics. This likelihood will be consid-
ered for subsequent adjustment. Treatment effects will be 
expressed as an adjusted proportional OR with 95% CI 
for treatment versus no treatment.
The limitation of the adjustment and the propen-
sity score is that they do not adjust for unobserved 
confounders that are likely to be present.
Therefore, we will also take a second approach (analysis 
at the ICU level) to examine the practice on ICP manage-
ment per ICU and/or geographic region. We will model 
the GOSE at 6 months as a function of treatment prefer-
ences of the ICU, defined as the percentage of indicated 
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patients who receive a certain treatment, with adjustment 
for relevant patients’ characteristics and a random inter-
cept for ICU. Such analysis accounts for other differ-
ences between ICUs than the treatment of interest and 
allows the causal inference in the presence of unobserved 
confounding and practice variation - as the patients who 
receive a certain treatment - because in the model their 
(confounding) conditions are assigned the ICU prefer-
ence as treatment, instead of their actual treatment.27 
Treatment effects will be expressed as an adjusted propor-
tional OR with 95% CI for 10% increase in treatment.
Missing baseline data will be imputed with multiple 
imputation (n=10). The patients with missing outcome 
will be excluded, but every attempt will be made to collect 
outcome data.
Subgroup analysis will be performed in the following 
subgroups: diagnosis (SAH, TBI and ICH), geographical 
region (high-, middle- and low-income countries) and 
disease severity.3–7
dIsCussIon
We aim to obtain data from a large cohort of ABI patients 
admitted to an ICU, and we expect around 50% with acute 
traumatic brain injury and 50% with acute non-traumatic 
brain injury (SAH and ICH). We will provide a detailed 
description of the patients’ characteristics, ICP manage-
ment strategies, resource use and their correlation to 
clinical outcomes. Furthermore, we will explore several 
aspects of ICP monitoring and ICP-related therapy, to 
investigate their variation across ICUs worldwide. The 
differences in the management of TBI and non-TBI 
patients’ treatment, including thresholds, therapeutic 
strategies and their potential association with outcomes, 
will be also described.
The results generated from this study will comple-
ment other large multicentre studies (CENTER-TBI, 
TRACK-TBI, etc) focusing on TBI practice. In addition, 
for the first time, we aim to collect large-scale data on ICP 
practice in SAH and ICH.
The worldwide scope of the SYNAPSE-ICU study 
requires a thorough study management plan, human 
resources management and expertise in data manage-
ment to face the challenges posed by such a large project. 
However, the global approach can be considered as the 
main strength and novelty of the study, since it allows 
to explore the clinical practice in geographical regions 
characterised by very different public health issues. The 
presence of centres in low- and middle-income countries 
will provide robust data about ICP monitoring in these 
regions, thus addressing an important knowledge gap 
and informing external validity of ongoing research on 
ICP.
The SYNAPSE-ICU study offers a unique opportunity 
to globally inform clinical guidelines regarding ICP 
measurement and treatment, eventually improving the 
outcome of the patients with TBI, SAH and ICH.
The observational nature of the study and the conse-
quent difficulty to draw causal inferences reliably accounts 
as the main limitation of the research. The aim of the 
study is hypothesis-generating for treatment effects to be 
assessed in large randomised clinical trials.
EthICs And dIssEMInAtIon
Ethics
Each National Coordinator will notify the relevant ethics 
committee, in compliance with the local legislation 
and rules. The study has been approved by the Ethics 
Committee ‘Brianza’ at the ASST-Monza (approval date: 
21 November 2017). Since the patients will not be able to 
provide an informed consent at the time of study recruit-
ment, each country will refer to the local/national law on 
the matter of lack of capacity. Generally, if the patients 
will regain capacity at the follow-up visit, they will be 
asked to provide the informed consent for the acute data 
and follow-up, or deny further research participation 
without any objection against the use for research of data 
collected during the acute phase, or deny further research 
participation and require the destruction of acute data 
collected. The study will be performed according to the 
Helsinki Declaration and the International Conference 
on Harmonisation for Good Clinical Practice.
dissemination
The SYNAPSE-ICU Steering Committee (SC) will 
consider any request on data sharing, and decisions 
will be made in relation to these requests by the Prin-
cipal Investigator (GC) after the first multicentre manu-
script has been published. Data will be made available to 
European Society of Intensive Care Medicine (ESICM) 
members and to the scientific community by means of 
abstract submitted to the ESICM annual conference and 
by scientific reports and original articles submitted to 
peer-reviewed journals. A writing committee, composed 
in part of the SC members, will draft the work and the SC 
members will be authors of the manuscript. Additional 
authorship of the main manuscript will follow the Inter-
national Committee of Medical Journal Editors (ICMJE) 
recommendations. National coordinators will be authors 
if they fulfil the ICMJE criteria and if they promote the 
enrolment of at least 500 patients in their country. All the 
participating centres will be recognised as contributors 
in the group authorship ‘SYNAPSE-ICU Collaborators’. 
The corresponding author will specify the group name 
and will clearly identify the group members who can take 
credit and responsibility for the work as collaborators. For 
each centre, a participant will be indicated in the group 
authorship list every 15 patients enrolled. The ESICM 
support will be acknowledged in all publication gener-
ated from the study.
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